ANI Pharmaceuticals (NASDAQ:ANIP) Share Price Passes Below 200 Day Moving Average of $61.19

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $61.19 and traded as low as $58.45. ANI Pharmaceuticals shares last traded at $58.53, with a volume of 324,176 shares.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on ANIP shares. Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Capital One Financial initiated coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price for the company. HC Wainwright lifted their price objective on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the company a “buy” rating in a report on Monday, May 13th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Buy” and an average target price of $81.00.

ANI Pharmaceuticals Stock Down 1.4 %

The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 36.58 and a beta of 0.81. The business’s 50-day moving average is $64.38 and its two-hundred day moving average is $61.26. The company has a quick ratio of 3.12, a current ratio of 3.95 and a debt-to-equity ratio of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.16. The company had revenue of $137.43 million for the quarter, compared to analyst estimates of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. Equities analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.34 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In related news, CEO Nikhil Lalwani sold 16,669 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $66.10, for a total transaction of $1,101,820.90. Following the sale, the chief executive officer now directly owns 377,505 shares of the company’s stock, valued at approximately $24,953,080.50. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other ANI Pharmaceuticals news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $67.25, for a total value of $1,345,000.00. Following the sale, the senior vice president now directly owns 253,226 shares of the company’s stock, valued at approximately $17,029,448.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Nikhil Lalwani sold 16,669 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $66.10, for a total transaction of $1,101,820.90. Following the completion of the sale, the chief executive officer now directly owns 377,505 shares in the company, valued at $24,953,080.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 156,688 shares of company stock worth $10,230,863. 12.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in shares of ANI Pharmaceuticals by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after buying an additional 17,460 shares in the last quarter. Rubric Capital Management LP increased its holdings in ANI Pharmaceuticals by 32.8% during the 4th quarter. Rubric Capital Management LP now owns 1,125,000 shares of the specialty pharmaceutical company’s stock valued at $62,032,000 after acquiring an additional 277,989 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 6.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 591,731 shares of the specialty pharmaceutical company’s stock valued at $32,628,000 after acquiring an additional 33,359 shares in the last quarter. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 10.8% during the fourth quarter. Global Alpha Capital Management Ltd. now owns 582,428 shares of the specialty pharmaceutical company’s stock worth $32,115,000 after buying an additional 56,900 shares in the last quarter. Finally, Ranger Investment Management L.P. grew its holdings in shares of ANI Pharmaceuticals by 1.8% during the fourth quarter. Ranger Investment Management L.P. now owns 434,617 shares of the specialty pharmaceutical company’s stock worth $23,965,000 after buying an additional 7,769 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.